Other secondary gout

GOUT_SCND

gout: A condition characterized by painful swelling of the joints, which is caused by deposition of urate crystals.

Suggest a new description

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

473681

1. Apply sex-specific rule

None

473681

2. Check conditions

None

473681

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 M10.4
  • Cause of death: ICD-10 M10.4

2 out of 7 registries used, show all original rules.

96

4. Check minimum number of events

None

96

5. Include endpoints

None

96

6. Filter based on genotype QC (FinnGen only)

95

Control definitions (FinnGen only)

Control exclude
GOUT

Extra metadata

First used in FinnGen datafreeze
DF2
Parent code in ICD-10
M10
Name in latin
Alia arthritis urica secundaria

Case counts by codes

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 964 358 599
Only index persons 824 302 522
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.02
Only index persons 0.02 0.01 0.02
Median age at first event (years)
Whole population 71.27 76.27 68.30
Only index persons 70.71 75.58 67.90

-FinnGen-

Key figures

All Female Male
Number of individuals 95 27 68
Unadjusted period prevalence (%) 0.03 0.01 0.03
Median age at first event (years) 67.55 63.94 68.99

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
96
Matched controls
961
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M10.4
ICD-10 Finland
Other secondary gout
+∞
138.3
96
*
M04AA01
ATC
allopurinol; systemic
19.6
34.7
61
78
M10.9
ICD-10 Finland
Gout, unspecified
29.0
27.8
38
21
M10.0
ICD-10 Finland
Idiopathic gout
26.1
17.5
24
12
C03CA01
ATC
furosemide; systemic
6.6
16.6
67
249
I50.9
ICD-10 Finland
Heart failure, unspecified
7.4
16.0
45
102
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
10.4
15.8
33
46
212
Kela drug reimbursment
Gout
+∞
13.9
13
*
N18.8
ICD-10 Finland
Other chronic renal failure
21.8
12.6
18
10
M10
ICD-10 Finland
Gout
13.8
12.3
21
19
I48
ICD-10 Finland
Atrial fibrillation and flutter
5.2
12.3
49
161
B01AA03
ATC
warfarin; systemic
5.1
12.1
48
156
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
22.6
12.1
17
9
I50.0
ICD-10 Finland
Congestive heart failure
7.3
11.8
30
56
A11CC03
ATC
alfacalcidol; systemic
21.9
10.7
15
8
205
Kela drug reimbursment
Chronic hypertension
4.4
10.5
51
196
ZXD05
NOMESCO Finland
Urgent procedure
4.1
9.6
50
201
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
16.1
9.0
14
10
I50.1
ICD-10 Finland
Left ventricular failure
7.9
8.8
20
31
C03DA01
ATC
spironolactone; oral
5.0
8.7
30
80
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
5.1
8.6
29
75
H02AB06
ATC
prednisolone; systemic
3.7
8.4
61
309
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.7
8.1
47
199
C07AB07
ATC
bisoprolol; oral
3.6
8.0
68
386
R06.0
ICD-10 Finland
Dyspnoea
3.9
8.0
40
150
N02AA05
ATC
oxycodone; systemic
4.6
7.9
30
87
C09AA02
ATC
enalapril; systemic
3.9
7.9
38
138
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
4.4
7.8
30
89
A46
ICD-10 Finland
Erysipelas
4.2
7.7
32
102
J01MA12
ATC
levofloxacin; systemic
3.9
7.4
34
118
M01AB01
ATC
indometacin; systemic, rectal
6.3
7.3
19
36
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.9
7.2
33
114
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.6
7.0
37
143
N03AX12
ATC
gabapentin; oral
4.3
6.9
27
80
A12AA04
ATC
calcium carbonate; oral
18.4
6.9
10
6
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
5.1
6.9
22
53
A10BH05
ATC
linagliptin; oral
7.2
6.8
16
26
TPH04
NOMESCO Finland
Cathetrisation of vein
3.7
6.8
33
119
WX002
NOMESCO Finland
Sedation and analgesia
3.7
6.8
33
119
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
4.0
6.6
28
90
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
5.5
6.6
19
41
B03XA02
ATC
darbepoetin alfa; parenteral
15.7
6.6
10
7
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
74.6
6.5
7
*
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
4.3
6.5
25
73
R10.1
ICD-10 Finland
Pain localized to upper abdomen
4.3
6.5
25
73
N19
ICD-10 Finland
Unspecified kidney failure
7.2
6.5
15
24
XFP20
NOMESCO Finland
Check up of cardiac pacemaker
6.0
6.4
17
33
137
Kela drug reimbursment
Uraemia requiring dialysis
+∞
6.3
6
*
B05DA
ATC
Isotonic solutions
+∞
6.3
6
*
M10.3
ICD-10 Finland
Gout due to impairment of renal function
+∞
6.3
6
*
E11.2
ICD-10 Finland
Type 2 diabetes mellitus, with renal complications
7.6
6.3
14
21
J01DB01
ATC
cefalexin; oral
4.0
6.1
84
613
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
4.3
6.1
23
66
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.9
6.1
59
339
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.0
6.0
25
78

Mortality – FinRegistry

Association

Association between endpoint GOUT_SCND and mortality.

Females

Parameter HR [95% CI] p-value
GOUT_SCND 2.432 [1.7, 3.49] < 0.001
Birth year 0.994 [0.99, 1.0] 0.198

During the follow-up period (1.1.1998 — 31.12.2019), 157 out of 306 females with GOUT_SCND died.

Males

Parameter HR [95% CI] p-value
GOUT_SCND 3.031 [2.18, 4.21] < 0.001
Birth year 0.986 [0.98, 1.0] 0.003

During the follow-up period (1.1.1998 — 31.12.2019), 239 out of 515 males with GOUT_SCND died.

Mortality risk

Mortality risk for people of age

years, who have GOUT_SCND.

N-year risk Females Males
1 0.272% 0.647%
5 1.404% 3.526%
10 3.392% 7.938%
15 6.578% 14.883%
20 11.242% 24.572%

Relationships between endpoints

Index endpoint: GOUT_SCND – Other secondary gout

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data